$0.50 EPS Expected for Anika Therapeutics Inc (ANIK)

July 17, 2017 - By Michael Collier

 $0.50 EPS Expected for Anika Therapeutics Inc (ANIK)
Investors sentiment decreased to 1.01 in 2016 Q4. Its down 0.25, from 1.26 in 2016Q3. It dived, as 17 investors sold Anika Therapeutics Inc shares while 53 reduced holdings. 20 funds opened positions while 51 raised stakes. 10.86 million shares or 0.92% less from 10.97 million shares in 2016Q3 were reported.
Earnest Prns Ltd Llc holds 1,500 shares or 0% of its portfolio. Moreover, Mcf Advsr Lc has 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK). 19,514 are held by Bankshares Of Montreal Can. Seaward Partnership accumulated 31,800 shares or 0.08% of the stock. Renaissance Tech Limited Liability Com stated it has 166,800 shares. Baltimore reported 0.01% stake. Royal Financial Bank Of Canada accumulated 37,763 shares or 0% of the stock. Pnc Ser has 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK) for 1,700 shares. Pennsylvania-based Federated Invsts Incorporated Pa has invested 0% in Anika Therapeutics Inc (NASDAQ:ANIK). Pub Sector Pension Invest Board holds 10,047 shares or 0% of its portfolio. Susquehanna Gru Limited Liability Partnership reported 0% stake. Johnson Fincl Group Incorporated holds 0% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK) for 500 shares. Rhumbline Advisers invested in 19,455 shares. Invesco Limited holds 42,535 shares. State Of Tennessee Treasury Department reported 11,778 shares stake.

Since February 22, 2017, it had 0 buys, and 3 insider sales for $833,696 activity. Cheung Sylvia sold $196,096 worth of Anika Therapeutics Inc (NASDAQ:ANIK) on Wednesday, February 22. $129,326 worth of Anika Therapeutics Inc (NASDAQ:ANIK) was sold by LAND RAYMOND J on Wednesday, February 22.

Investors wait Anika Therapeutics Inc (NASDAQ:ANIK) to report on July, 26. its quarterly earnings Wall Street analysts expect $0.50 EPS, down $0.07 or 12.28 % from last year’s $0.57 same quarter earnings. This translates into $7.32 million profit for ANIK giving the stock a 23.24 P/E. This is assuming the current $0.50 EPS is accurate. Anika Therapeutics Inc’s Wall Street analysts see 35.14 % EPS growth, taking into account the $0.37 EPS reproted in the previous quarter, The stock increased 0.76% or $0.35 during the last trading session, reaching $46.47. About 75,267 shares traded. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 4.53% since July 18, 2016 and is uptrending. It has underperformed by 12.17% the S&P500.

Anika Therapeutics Inc (NASDAQ:ANIK) Ratings Coverage

Among 3 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Anika Therapeutics had 6 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Outperform” rating given on Monday, October 12 by Barrington Research. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Market Perform” rating given on Wednesday, April 27 by Northland Capital. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Equal Weight” rating given on Friday, August 28 by First Analysis. Zacks upgraded Anika Therapeutics Inc (NASDAQ:ANIK) rating on Wednesday, August 26. Zacks has “Hold” rating and $37 target. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Outperform” rating given on Friday, February 26 by Northland Capital. The firm has “Outperform” rating given on Thursday, July 30 by Northland Capital.

Anika Therapeutics, Inc. is an orthopedic medicines company. The company has market cap of $680.26 million. The Firm is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid technology. It has a 22.46 P/E ratio. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA scaffold to aid cartilage repair and regeneration.

More notable recent Anika Therapeutics Inc (NASDAQ:ANIK) news were published by: Nasdaq.com which released: “4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings” on July 17, 2017, also Businesswire.com with their article: “Anika Announces Publication of Phase III Data Demonstrating the Efficacy and …” published on May 22, 2017, Globenewswire.com published: “Anika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock Market …” on February 27, 2017. More interesting news about Anika Therapeutics Inc (NASDAQ:ANIK) were released by: Businesswire.com and their article: “Anika Announces $5 Million Milestone Payment from US Commercial Sales of MONOVISC” published on July 17, 2017 as well as Businesswire.com‘s news article titled: “-T To Relieve Pain and Restore Function of Tendons Damaged by Chronic Injury” with publication date: December 19, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.